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From the Celgene CorporationTwo reports in a recent issue, by Arpinati et al. [1] and the body, every sample is likely to contain 1 or more. An
Goldman [2], touch on how to interpret results of high-
sensitivity PCR testing for BCR/ABL1 mRNA transcripts in
persons with chronic myelogenous leukemia (CML). The
authors sensibly argue that an occasional positive test should
not be interpreted as indicating clinical relapse and should
not precipitate an intervention. They then offer intriguing,
sometimes complex, explanations of this observation.
Might I add another? Ten years ago, in an interesting,
dense, and completely ignored report by Butturini et al.[3]
we showed, using mathematical modeling, that when there
are few residual leukemia cells in a person, say <10E4
(so-called minimal residual disease [MRD]), the small
volume of blood and bonemarrow samples we test is the key
determinant of whether a MRD test will be positive or
negative rather than test sensitivity. Consequently, in
a personwith CML receiving a tyrosine kinase inhibitor or an
allotransplantation, one would expect results of BCR/ABL1
transcript testing to alternate between positive and negative
based solely on sampling errors, even when numbers of
residual CML cells in that person are constant or decreasing.
This is compatible with the data of Arpinati and comment
by Goldman. This variability in results of MRD testing should
be distinguished from tests that are repeatedly positive,
especially tests which indicate an increasing proportion of
CML cells. This is because at residual leukemia cells >10E4,
test sensitivity, rather than sampling error, predominates.
Namely, because there are many residual leukemia cells in1083-8791/$ e see front matter  2013 American Society for Blood and Marrowimportant corollary is that observations, such as a higher
proportion of leukemia relapses in persons who are
PCR-positive versus those who are PCR-negative, is funda-
mentally a self-fulﬁlling prophesy and does not prove the
PCR test is a reliable surrogate for relapse in persons with few
residual leukemia cells. This incorrect conclusion is common
in interpreting results of MRD testing and not only in persons
with CML.
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5Masonic Cancer Center, University of Minnesota, Minneapolis, MinnesotaWe previously reported that the infusion of ex vivo control subjects [1]. We did not observe an increased inci-
expanded umbilical cord blood (UCB)-derived natural regu-
latory T cells (nTregs) infused immediately after UCB trans-
plantation was associated with a reduced incidence of acute
graft-versus-host disease (GVHD) relative to historicaldence of opportunistic infections or relapse, suggesting the
transient nature of nTreg provided sufﬁcient immune
suppression to control GVHD without long-term deleterious
effects. However, we hypothesized that early side effectsTransplantation.
